aberrations and in shape adequate to tolerate FCR therapy, may still be good candidates for that latter, While using the advantage remaining that this treatment method could be done in 6 months even though ibrutinib has to be taken indefinitely.Some diploma of immunophenotype overlap amid CLL, marginal zone lymphoma, and lymphoplasmacytic lymphoma